Opaleye Management Inc.

About Opaleye Management Inc.

Opaleye Management Inc. is a U.S.-based investment management firm with public-market exposure to several listed biopharmaceutical companies, including Eton Pharmaceuticals, Harrow Health, Protara Therapeutics, and Tracon Pharmaceuticals. In SEC filings, the firm is described as the investment manager of the Opaleye fund and, in some cases, as portfolio manager for separately managed accounts. Its most visible public role is that of a reporting person and significant shareholder in NYSE/NASDAQ-listed issuers, rather than a traditional operating executive inside a single company. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1595855/000149315220005929/formsc13ga.htm?utm_source=openai)) From a career-path and expertise standpoint, the public record points to an institutional investor focused on healthcare and biotech equity positions. The filings do not provide a detailed operating history or a list of internal executive decisions, but they do show recurring involvement with small- and mid-cap pharmaceutical names. That pattern suggests experience in fundamental analysis, portfolio construction, regulatory monitoring, and shareholder governance for public issuers. Rather than claiming unsupported operational milestones, the safest accurate characterization is that Opaleye Management Inc. has maintained active investment relationships with companies such as Eton, Harrow Health, Protara, and Tracon, indicating a sector specialization in public-life-sciences investing. Where an individual is identified in the filings, James Silverman is named as President of the Investment Manager. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1595855/000149315220018377/sc13da.htm?utm_source=openai)) Notable public “decisions” are best described at a high level: the firm’s SEC footprint shows sustained ownership disclosure activity across multiple healthcare issuers, including beneficial ownership reporting and position updates. That makes Opaleye Management Inc. relevant in corporate governance discussions, proxy contexts, and capital-markets analysis for U.S. listed biotech companies. For SEO purposes, it is accurate to frame the firm as a specialized investment manager with recognized involvement in publicly traded healthcare companies, while avoiding unverified claims about internal strategic actions or undisclosed mandates. ([ir.etonpharma.com](https://ir.etonpharma.com/sec-filings/sec-filing/4/0001493152-24-040490?utm_source=openai))